ClinicalTrials.gg
CompletedNCT02184195POLOUpdated Sep 13, 2023Results posted

Olaparib in gBRCA Mutated Pancreatic Cancer Whose Disease Has Not Progressed on First Line Platinum-Based Chemotherapy

A Phase 3 interventional study of Olaparib and Olaparib in Germline BRCA1/2 Mutations and and Metastatic Adenocarcinoma of the Pancreas, sponsored by AstraZeneca. Completed at 103 sites in 12 countries. Open to participants aged 18 Years to 130 Years. Per ClinicalTrials.gov, last updated 2023-09-13.

Sponsored by AstraZeneca · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
154
Allocation
Randomized
Ages
18 Years to 130 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 14 studies testing olaparib in Pancreatic Neoplasms — 4 open to participants now, 7 under way, none of them phase 3. olaparib · Pancreatic Neoplasms.

Enrollment
2nd of 14
154 · median 30
Started
2014
the only one that year
Phase 3
Only one
of the 14
Registered
3rd of 14
by date
Lead sponsor
2 of 14
AstraZeneca

Among the 14 studies testing olaparib in Pancreatic Neoplasms, this one is the 2nd largest by enrollment, is the only one that started in 2014, is the only one in phase 3, and was the 3rd registered.

Pancreatic Neoplasms

3,897 studies on the registry are indexed under Pancreatic Neoplasms; 1,003 are open to participants now.

Browse Pancreatic Neoplasms studies →

Open to participants now

4 of the 14 studies testing olaparib in Pancreatic Neoplasms are open now, in 5 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

About olaparib

olaparib: first FDA approval 2014 (LYNPARZA), first EMA approval 2014. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 743 Pancreatic Neoplasms studies recruiting now, 477 (64%) set no upper age limit and 151 (20%) stop at 75 or younger; 40 take children under 18; 59 take healthy volunteers.

This study: 18 Years to 130 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 14 studies testing olaparib in Pancreatic Neoplasms, or all of them as a file.
02

Study summary

A Phase III, Randomised, Double Blind, Placebo Controlled, Multicentre Study of Maintenance Olaparib Monotherapy in Patients with gBRCA Mutated Metastatic Pancreatic Cancer whose Disease Has Not Progressed on First Line Platinum Based Chemotherapy

Read the detailed description

Approximately 145 patients will be randomised using an Interactive Voice Response System /Interactive Web Response System (IVR/IWR system) in a 3:2 ratio (Olaparib:placebo) to the treatments as specified below:

  • Olaparib tablets p.o. 300 mg twice daily
  • Matching placebo tablets p.o. twice daily Eligible patients will be those patients with pancreas cancer previously treated for metastatic disease who have not progressed following completion of at least 16 weeks (can be more) of first line platinum-based chemotherapy. All patients must have a known deleterious or suspected deleterious germline BRCA mutation to be randomised; this may have been determined prior to enrolment into the study or may be assessed as part of the enrolment procedure for the study (via centrally provided MyriadIntegrated BRAC.

Patients will be randomised within 6 weeks after their last dose of chemotherapy (last dose is the day of the last infusion) and treatment started as soon as possible but no less than 4 and no more than 8 weeks of the last chemotherapy dose. At the time of starting protocol treatment, all previous chemotherapy treatment should be discontinued.

Following randomisation, patients will attend clinic visits weekly for the first 4 weeks of treatment (Days 8, 15, 22 and 29). Patients will then attend clinic visits every 4 weeks whilst on study treatment. Patients should continue to receive study treatment until objective radiological disease progression as per RECIST as assessed by the investigator and as long as in the investigator's opinion they are benefiting from treatment and they do not meet any other discontinuation criteria.

Once a patient has progressed the patient will be followed for second progression (PFS2) every 8 weeks and then survival until the final analysis.

03

Conditions studied

  • Germline BRCA1/2 Mutations and
  • Metastatic Adenocarcinoma of the Pancreas

Keywords

  • BRCA, metastatic adenocarcinoma pancreas, maintenance olaparib monotherapy, first line platinum chemotherapy, pancreatic cancer, PARP inhibitor
04

Who can participate

Ages eligible
18 Years to 130 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria

  • or cytologically confirmed pancreas adenocarcinoma receiving initial chemotherapy for disease and without evidence of disease progression on treatment
  • Patients with and/or non-measurable or no evidence of disease assessed at baseline by CT (or MRI where CT is ) will be entered in this study.
  • Documented mutation in gBRCA1 or gBRCA2 that is predicted to be deleterious or suspected deleterious
  • Patients are on treatment with a platinum-based (cisplatin, carboplatin or oxaliplatin) regimen for metastatic pancreas cancer, have received a minimum of 16 weeks of continuous platinum treatment and have no evidence of progression based on investigator's opinion.
  • Patients who have received platinum as potentially curative treatment for a prior cancer (eg ovarian cancer) or as /neoadjuvant treatment for pancreas cancer are eligible provided at least 12 months have elapsed between the last dose of platinum-based treatment and initiation of the platinum-based chemotherapy for metastatic pancreas cancer.

Major Exclusion Criteria:

  • gBRCA1 and/or gBRCA2 mutations that are considered to be non detrimental (eg, "Variants of uncertain clinical significance" or "Variant of unknown significance" or "Variant, favour polymorphism" or "benign polymorphism" etc.)
  • Progression of tumour between start of first line platinum based chemotherapy for metastatic pancreas cancer and randomisation.
  • Cytotoxic chemotherapy or non-hormonal targeted therapy within 28 days of Cycle

    1 Day 1 is not permitted.

  • Exposure to an product within 30 days or 5 half lives (whichever is longer) prior to randomisation
  • Any previous treatment with a PARP inhibitor, including Olaparib
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
154 participants (actual)

Study arms

  • Experimental
    Olaparib

    Olaparib tablets po. 300 mg twice daily

    Drug: Olaparib

  • Placebo comparator
    Placebo

    Placebo tablets twice daily

    Drug: Placebo

Interventions

  • Tablet -100mg

  • Tablet-150mg

  • DrugPlacebo

    Match Olaparib 100mg placebo

  • DrugPlacebo

    Match Olaparib 150mg placebo

06

What researchers measure

Primary outcomes

  1. Progression-free Survival (PFS) by Blinded Independent Central Review (BICR) Using Modified Response Evaluation Criteria in Solid Tumours. This Study Used Modified RECIST Version (v) 1.1 (RECIST v1.1)

    To determine the efficacy of olaparib maintenance monotherapy compared to placebo by PFS. The PFS was defined as the time from randomisation until the date of objective radiological disease progression according to modified RECIST v1.1 or death (by any cause in the absence of disease progression) regardless of whether the patient withdrew from randomized therapy or received another anticancer therapy prior to disease progression.

    Time frame: Up to 4 years

Secondary outcomes

  1. Overall Survival (OS)

    To determine the efficacy by assessment of OS of olaparib maintenance monotherapy compared to placebo. The OS was defined as the time from the date of randomization until death due to any cause.

    Time frame: Upto 4 years

  2. Time From Randomisation to Second Progression (PFS2)

    To determine efficacy by assessment of PFS2 of olaparib maintenance monotherapy compared to placebo. The PFS2 was defined as the time from the date of randomisation to the earliest of the progression event subsequent to that used for the primary variable PFS or death.

    Time frame: Up to 4 years

  3. Time From Randomisation to Second Subsequent Therapy or Death (TSST)

    To determine the efficacy by assessment of TSST of olaparib maintenance monotherapy compared to placebo. The TSST was defined as time to second subsequent therapy or death.

    Time frame: Up to 4 years

  4. Time From Randomisation to First Subsequent Therapy or Death (TFST)

    To determine the efficacy by assessment of TFST of olaparib maintenance monotherapy compared to placebo. The TFST was defined as time to first subsequent therapy or death.

    Time frame: Up to 4 years

  5. Time From Randomisation to Study Treatment Discontinuation or Death (TDT)

    To determine the efficacy by assessment of TDT compared to placebo. compared to placebo. The TDT was defined as time to study treatment discontinuation or death.

    Time frame: Up to 4 years

  6. Number of Participants With Objective Response Rate (ORR) by BICR Using Modified RECIST 1.1

    To determine efficacy by assessment of objective response rate according to modified RECIST 1.1 of olaparib maintenance monotherapy compared to placebo. The ORR is defined as the number of with a BoR of CR and PR according to the BICR data divided by the number of patients in the treatment group with measurable disease at baseline.

    Time frame: Up to 4 years

  7. Disease Control Rate (DCR) by BICR Using Modified RECIST 1.1

    Efficacy by assessment of disease control rate according to modified RECIST 1.1 of olaparib maintenance monotherapy compared to placebo.

    Time frame: At 16 weeks

  8. Adjusted Mean Change From Baseline up to 6 Months in Global Quality of Life (QoL) Score From the EORTC-QLQ-C30 Questionnaire

    To assess the effect of olaparib on health-related quality of life (QoL) as measured by the EORTC-QLQ-C30 global QoL scale. The EORTC-QLQ-C30 is defined as EORTC QLQ-C30: a questionnaire (30 questions) used to evaluate disease symptoms, functional impacts (eg, physical functioning), and HRQoL and to characterize clinical benefit from the patient perspective. The HRQoL score ranges from 0 to 100. A higher score indicates better QoL. A score change of 10 points was pre-defined as clinically meaningful. bd twice daily.

    Time frame: From baseline up to 6 months

  9. Number of Participants With Adverse Events (AEs)

    To assess the safety and tolerability of olaparib maintenance monotherapy. SAE: serious adverse events CTCAE: Common Terminology Criteria for Adverse Events

    Time frame: Up to 4 years

07

Results

Posted Jan 27, 2020

Participant flow

This study randomised patients at a total of 59 study centres in 12 countries: United States of America (13), Germany (8), France (7), Israel (7), Spain (7), United Kingdom (6), Italy (4), Belgium (2), Republic of Korea (2), Australia (1), Canada (1) and Netherlands (1).

Participant flow — Overall Study
MilestoneOlaparib 300 mg Twice Daily (bd)Placebo
Started9262
Completed197
Not completed7355
Withdrew: Patient decision52
Withdrew: Eligibility criteria not fulfilled01
Withdrew: Death6744
Withdrew: Lost to follow-up15
Withdrew: Other03

Outcome measures

PrimaryProgression-free Survival (PFS) by Blinded Independent Central Review (BICR) Using Modified Response Evaluation Criteria in Solid Tumours. This Study Used Modified RECIST Version (v) 1.1 (RECIST v1.1)

To determine the efficacy of olaparib maintenance monotherapy compared to placebo by PFS. The PFS was defined as the time from randomisation until the date of objective radiological disease progression according to modified RECIST v1.1 or death (by any cause in the absence of disease progression) regardless of whether the patient withdrew from randomized therapy or received another anticancer therapy prior to disease progression.

Time frame:
Up to 4 years
Reported as:
Median · Months
Progression-free Survival (PFS) by Blinded Independent Central Review (BICR) Using Modified Response Evaluation Criteria in Solid Tumours. This Study Used Modified RECIST Version (v) 1.1 (RECIST v1.1)
MonthsOlaparib 300 mg Twice Daily (bd)Placebo
Progression-free Survival (PFS) by Blinded Independent Central Review (BICR) Using Modified Response Evaluation Criteria in Solid Tumours. This Study Used Modified RECIST Version (v) 1.1 (RECIST v1.1)7.4 (4.14 to 11.01)3.8 (3.52 to 4.86)
Statistical analysis
  • Olaparib 300 mg Twice Daily (bd) vs Placebo · Log-rank test · p = 0.0038 · Hazard ratio (hr): 0.531 · 95% CI 0.346 to 0.815
SecondaryOverall Survival (OS)

To determine the efficacy by assessment of OS of olaparib maintenance monotherapy compared to placebo. The OS was defined as the time from the date of randomization until death due to any cause.

Time frame:
Upto 4 years
Reported as:
Median · Months
Overall Survival (OS)
MonthsOlaparib 300 mg Twice Daily (bd)Placebo
Overall Survival (OS)19.0 (15.28 to 26.32)19.2 (14.32 to 26.12)
Statistical analysis
  • Olaparib 300 mg Twice Daily (bd) vs Placebo · Log-rank test · p = 0.3487 · Hazard ratio (hr): 0.831 · 95% CI 0.564 to 1.224
SecondaryTime From Randomisation to Second Progression (PFS2)

To determine efficacy by assessment of PFS2 of olaparib maintenance monotherapy compared to placebo. The PFS2 was defined as the time from the date of randomisation to the earliest of the progression event subsequent to that used for the primary variable PFS or death.

Time frame:
Up to 4 years
Reported as:
Median · Months
Time From Randomisation to Second Progression (PFS2)
MonthsOlaparib 300 mg Twice Daily (bd)Placebo
Time From Randomisation to Second Progression (PFS2)16.9 (8.21 to 23.85)9.3 (8.15 to 13.54)
Statistical analysis
  • Olaparib 300 mg Twice Daily (bd) vs Placebo · Log-rank test · p = 0.0613 · Hazard ratio (hr): 0.659 · 95% CI 0.426 to 1.020
SecondaryTime From Randomisation to Second Subsequent Therapy or Death (TSST)

To determine the efficacy by assessment of TSST of olaparib maintenance monotherapy compared to placebo. The TSST was defined as time to second subsequent therapy or death.

Time frame:
Up to 4 years
Reported as:
Median · Months
Time From Randomisation to Second Subsequent Therapy or Death (TSST)
MonthsOlaparib 300 mg Twice Daily (bd)Placebo
Time From Randomisation to Second Subsequent Therapy or Death (TSST)14.9 (9.13 to 19.78)9.6 (8.34 to 12.98)
Statistical analysis
  • Olaparib 300 mg Twice Daily (bd) vs Placebo · Log-rank test · p = 0.0111 · Hazard ratio (hr): 0.611 · 95% CI 0.418 to 0.894
SecondaryTime From Randomisation to First Subsequent Therapy or Death (TFST)

To determine the efficacy by assessment of TFST of olaparib maintenance monotherapy compared to placebo. The TFST was defined as time to first subsequent therapy or death.

Time frame:
Up to 4 years
Reported as:
Median · Months
Time From Randomisation to First Subsequent Therapy or Death (TFST)
MonthsOlaparib 300 mg Twice Daily (bd)Placebo
Time From Randomisation to First Subsequent Therapy or Death (TFST)9.0 (6.21 to 12.85)5.4 (3.94 to 6.21)
Statistical analysis
  • Olaparib 300 mg Twice Daily (bd) vs Placebo · Log-rank test · p = <0.0001 · Hazard ratio (hr): 0.442 · 95% CI 0.297 to 0.658
SecondaryTime From Randomisation to Study Treatment Discontinuation or Death (TDT)

To determine the efficacy by assessment of TDT compared to placebo. compared to placebo. The TDT was defined as time to study treatment discontinuation or death.

Time frame:
Up to 4 years
Reported as:
Median · Months
Time From Randomisation to Study Treatment Discontinuation or Death (TDT)
MonthsOlaparib 300 mg Twice Daily (bd)Placebo
Time From Randomisation to Study Treatment Discontinuation or Death (TDT)7.5 (5.52 to 10.97)3.8 (3.61 to 4.80)
Statistical analysis
  • Olaparib 300 mg Twice Daily (bd) vs Placebo · Log-rank test · p = <0.0001 · Hazard ratio (hr): 0.425 · 95% CI 0.289 to 0.627
SecondaryNumber of Participants With Objective Response Rate (ORR) by BICR Using Modified RECIST 1.1

To determine efficacy by assessment of objective response rate according to modified RECIST 1.1 of olaparib maintenance monotherapy compared to placebo. The ORR is defined as the number of with a BoR of CR and PR according to the BICR data divided by the number of patients in the treatment group with measurable disease at baseline.

Time frame:
Up to 4 years
Reported as:
Count of participants · Participants
Number of Participants With Objective Response Rate (ORR) by BICR Using Modified RECIST 1.1
ParticipantsOlaparib 300 mg Twice Daily (bd)Placebo
Number of Participants With Objective Response Rate (ORR) by BICR Using Modified RECIST 1.12211
Statistical analysis
  • Olaparib 300 mg Twice Daily (bd) vs Placebo · Regression, Logistic · p = 0.3273 · Odds ratio (or): 1.520 · 95% CI 0.668 to 3.610
SecondaryDisease Control Rate (DCR) by BICR Using Modified RECIST 1.1

Efficacy by assessment of disease control rate according to modified RECIST 1.1 of olaparib maintenance monotherapy compared to placebo.

Time frame:
At 16 weeks
Reported as:
Number · Participants
Disease Control Rate (DCR) by BICR Using Modified RECIST 1.1
ParticipantsOlaparib 300 mg Twice Daily (bd)Placebo
Yes5124
No3434
Not evaluable/missing74
SecondaryAdjusted Mean Change From Baseline up to 6 Months in Global Quality of Life (QoL) Score From the EORTC-QLQ-C30 Questionnaire

To assess the effect of olaparib on health-related quality of life (QoL) as measured by the EORTC-QLQ-C30 global QoL scale. The EORTC-QLQ-C30 is defined as EORTC QLQ-C30: a questionnaire (30 questions) used to evaluate disease symptoms, functional impacts (eg, physical functioning), and HRQoL and to characterize clinical benefit from the patient perspective. The HRQoL score ranges from 0 to 100. A higher score indicates better QoL. A score change of 10 points was pre-defined as clinically meaningful. bd twice daily.

Time frame:
From baseline up to 6 months
Reported as:
Mean · Unit on scale
Adjusted Mean Change From Baseline up to 6 Months in Global Quality of Life (QoL) Score From the EORTC-QLQ-C30 Questionnaire
Unit on scaleOlaparib 300 mg Twice Daily (bd)Placebo
Adjusted Mean Change From Baseline up to 6 Months in Global Quality of Life (QoL) Score From the EORTC-QLQ-C30 Questionnaire-1.03 (-3.826 to 1.759)1.18 (-2.585 to 4.939)
Statistical analysis
  • Olaparib 300 mg Twice Daily (bd) vs Placebo · Mixed Models Analysis · p = 0.355 · Mean difference (final values): -2.21 · 95% CI -6.917 to 2.496
SecondaryNumber of Participants With Adverse Events (AEs)

To assess the safety and tolerability of olaparib maintenance monotherapy. SAE: serious adverse events CTCAE: Common Terminology Criteria for Adverse Events

Time frame:
Up to 4 years
Reported as:
Number · Participants
Number of Participants With Adverse Events (AEs)
ParticipantsOlaparib 300 mg Twice Daily (bd)Placebo
Any AE8956
Any AE of CTCAE Grade 3 or higher4415
Any AE with outcome = death10
Any SAE (including events with outcome = death)2810
AnyAE leading to withdrawal of olaparib/placebo81
Any AE leading to dose interruption384
Any AE leading to dose reduction163

Adverse events

Collected over From informed consent until 30 days after last dose + subsequent treatment-related events reported (maximum up to 4 years).. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Olaparib 300 mg Twice Daily (bd)68/92 (73.9%)28/90 (31.1%)89/90 (98.9%)
Placebo52/62 (83.9%)10/61 (16.4%)56/61 (91.8%)
Most frequent serious events
Showing 10 of 45
Most frequent serious events
EventOlaparib 300 mg Twice Daily (bd)Placebo
AnaemiaBlood and lymphatic system disorders7/900/61
VomitingGastrointestinal disorders1/903/61
Abdominal painGastrointestinal disorders4/901/61
PyrexiaGeneral disorders0/902/61
CholangitisHepatobiliary disorders2/901/61
Febrile NeutropeniaBlood and lymphatic system disorders0/901/61
HyperglycaemiaMetabolism and nutrition disorders0/901/61
Embolic strokeNervous system disorders0/901/61
Cardiac failureCardiac disorders1/901/61
Renal failureRenal and urinary disorders0/901/61
Most frequent other events
Showing 10 of 53
Most frequent other events
EventOlaparib 300 mg Twice Daily (bd)Placebo
NauseaGastrointestinal disorders44/9015/61
FatigueGeneral disorders42/9016/61
DiarrhoeaGastrointestinal disorders34/9010/61
Abdominal painGastrointestinal disorders26/9015/61
AnaemiaBlood and lymphatic system disorders26/9010/61
ConstipationGastrointestinal disorders25/907/61
Back painMusculoskeletal and connective tissue disorders24/9013/61
Decreased appetiteMetabolism and nutrition disorders24/904/61
VomitingGastrointestinal disorders23/909/61
ArthralgiaMusculoskeletal and connective tissue disorders19/9011/61

Baseline characteristics

Full analysis set consisted of all randomised patients analysed on an intent to treat basis.

Age, Continuous
Age, Continuous(Years)Olaparib 300 mg Twice Daily (bd)PlaceboTotal
Mean58.2 ± 10.2756.4 ± 9.0757.5 ± 9.81
Sex: Female, Male
Sex: Female, Male(Participants)Olaparib 300 mg Twice Daily (bd)PlaceboTotal
Female393170
Male533184
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Olaparib 300 mg Twice Daily (bd)PlaceboTotal
Hispanic or Latino426
Not Hispanic or Latino8860148
Unknown or Not Reported000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Olaparib 300 mg Twice Daily (bd)PlaceboTotal
American Indian or Alaska Native101
Asian426
Native Hawaiian or Other Pacific Islander000
Black or African American505
White8259141
More than one race000
Unknown or Not Reported011
08

Study locations

103 sites
  • Research Site
    Gilbert, Arizona 85234, United States
  • Research Site
    Orange, California 92868, United States
  • Research Site
    Stanford, California 94305-5720, United States
  • Research Site
    Aurora, Colorado 80045, United States
  • Research Site
    New Haven, Connecticut 06510, United States
  • Research Site
    Boca Raton, Florida 33486, United States
  • Research Site
    Miami, Florida 33136, United States
  • Research Site
    Chicago, Illinois 60637, United States
  • Research Site
    Baltimore, Maryland 21287, United States
  • Research Site
    Boston, Massachusetts 02215, United States
  • Research Site
    Saint Louis, Missouri 63110, United States
  • Research Site
    Commack, New York 11725, United States
  • Research Site
    New York, New York 10016, United States
  • Research Site
    New York, New York 10022, United States
  • Research Site
    New York, New York 10032, United States
  • Research Site
    New York, New York 10065, United States
  • Research Site
    Columbus, Ohio 43210, United States
  • Research Site
    Philadelphia, Pennsylvania 19111, United States
  • Research Site
    Houston, Texas 77030, United States
  • Research Site
    Seattle, Washington 98104, United States
  • Research Site
    Campbelltown, 2560, Australia
  • Research Site
    Randwick, 2031, Australia
  • Research Site
    St Leonards, 2065, Australia
  • Research Site
    Antwerpen, 2020, Belgium
  • Research Site
    Brussel, 1070, Belgium
  • Research Site
    Leuven, 3000, Belgium
  • Research Site
    London, Ontario N6A 4L6, Canada
  • Research Site
    Montreal, Quebec H3T 1E2, Canada
  • Research Site
    Sherbrooke, Quebec J1G 2E8, Canada
  • Research Site
    Toronto, M5G 2M9, Canada
  • Research Site
    Amiens, 80054, France
  • Research Site
    Besançon, 25000, France
  • Research Site
    Bordeaux, 33075, France
  • Research Site
    Brest Cedex, 29609, France
  • Research Site
    Clichy Cedex, 92118, France
  • Research Site
    La Roche sur Yon, 85925, France
  • Research Site
    Lille, 59020, France
  • Research Site
    Lyon Cedex 03, 69437, France
  • Research Site
    Nice, 06189, France
  • Research Site
    Paris CEDEX 14, 75674, France
  • Research Site
    Paris, 75014, France
  • Research Site
    Poitiers, 86021, France
  • Research Site
    STRASBOURG Cedex, 67065, France
  • Research Site
    Toulouse, 31059, France
  • Research Site
    Villejuif, 94800, France
  • Research Site
    Berlin, 10967, Germany
  • Research Site
    Berlin, D-13353, Germany
  • Research Site
    Bochum, 44791, Germany
  • Research Site
    Bonn, 53127, Germany
  • Research Site
    Dresden, 01307, Germany
  • Research Site
    Frankfurt am Main, 60596, Germany
  • Research Site
    Hamburg, 20246, Germany
  • Research Site
    Hamburg, 22291, Germany
  • Research Site
    Hannover, 30625, Germany
  • Research Site
    Leipzig, 04103, Germany
  • Research Site
    München, 81675, Germany
  • Research Site
    Schweinfurt, 97422, Germany
  • Research Site
    Ulm, 89081, Germany
  • Research Site
    Beer Sheva, 84101, Israel
  • Research Site
    Haifa, 3109601, Israel
  • Research Site
    Holon, 58100, Israel
  • Research Site
    Nahariya, 22100, Israel
  • Research Site
    Petah Tikva, 4941492, Israel
  • Research Site
    Ramat Gan, 5265601, Israel
  • Research Site
    Rehovot, 76100, Israel
  • Research Site
    Tel Aviv, 6423906, Israel
  • Research Site
    Zefir, 7030000, Israel
  • Research Site
    Bologna, 40138, Italy
  • Research Site
    Milano, 20132, Italy
  • Research Site
    Milano, 20133, Italy
  • Research Site
    Padova, 35128, Italy
  • Research Site
    Parma, 43126, Italy
  • Research Site
    Pescara, 65100, Italy
  • Research Site
    Roma, 00128, Italy
  • Research Site
    Roma, 00144, Italy
  • Research Site
    San Giovanni Rotondo, 71013, Italy
  • Research Site
    Verona, 37134, Italy
  • Research Site
    Seongnam-si, 13620, Korea, Republic of
  • Research Site
    Seoul, 03080, Korea, Republic of
  • Research Site
    Seoul, 6351, Korea, Republic of
  • Research Site
    Amsterdam, 1105 AZ, Netherlands
  • Research Site
    Barcelona, 08035, Spain
  • Research Site
    Girona, 17007, Spain
  • Research Site
    L'Hospitalet de Llobregat, 08907, Spain
  • Research Site
    Madrid, 28007, Spain
  • Research Site
    Madrid, 28034, Spain
  • Research Site
    Madrid, 28041, Spain
  • Research Site
    Madrid, 28050, Spain
  • Research Site
    Málaga, 29010, Spain
  • Research Site
    Pamplona, 31008, Spain
  • Research Site
    Sabadell, 8208, Spain
  • Research Site
    Santiago de Compostela, 15706, Spain
  • Research Site
    Valencia, 46009, Spain
  • Research Site
    Zaragoza, 50009, Spain
  • Research Site
    Edinburgh, EH4 2XR, United Kingdom
  • Research Site
    Glasgow, G12 0YN, United Kingdom
  • Research Site
    Liverpool, L69 3GA, United Kingdom
  • Research Site
    London, SE5 9RS, United Kingdom
  • Research Site
    London, WC1E 6AG, United Kingdom
  • Research Site
    Manchester, M20 4BX, United Kingdom

Showing the first 100 of 103 sites across 12 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Golan T, Hammel P, Reni M, Van Cutsem E, Macarulla T, Hall MJ, Park JO, Hochhauser D, Arnold D, Oh DY, Reinacher-Schick A, Tortora G, Algul H, O'Reilly EM, McGuinness D, Cui KY, Schlienger K, Locker GY, Kindler HL. Maintenance Olaparib for Germline BRCA-Mutated Metastatic Pancreatic Cancer. N Engl J Med. 2019 Jul 25;381(4):317-327. doi: 10.1056/NEJMoa1903387. Epub 2019 Jun 2. PubMed 31157963 ↗
  • Amin S, Joo S, Nolte S, Yoo HK, Patel N, Byrnes HF, Costa-Cabral S, Johnson CD. Health-related quality of life scores of metastatic pancreatic cancer patients responsive to first line chemotherapy compared to newly derived EORTC QLQ-C30 reference values. BMC Cancer. 2022 May 20;22(1):563. doi: 10.1186/s12885-022-09661-7. PubMed 35596182 ↗
  • Li N, Zheng H, Huang Y, Zheng B, Cai H, Liu M. Cost-Effectiveness Analysis of Olaparib Maintenance Treatment for Germline BRCA-Mutated Metastatic Pancreatic Cancer. Front Pharmacol. 2021 Apr 20;12:632818. doi: 10.3389/fphar.2021.632818. eCollection 2021. PubMed 33959007 ↗
  • Zhan M, Zheng H, Yang Y, He Z, Xu T, Li Q. Cost-Effectiveness Analysis of Maintenance Olaparib in Patients with Metastatic Pancreatic Cancer and a Germline BRCA1/2 Mutation Based on the POLO Trial. Cancer Manag Res. 2020 Dec 16;12:12919-12926. doi: 10.2147/CMAR.S283169. eCollection 2020. PubMed 33364840 ↗
  • Golan T, Kindler HL, Park JO, Reni M, Macarulla T, Hammel P, Van Cutsem E, Arnold D, Hochhauser D, McGuinness D, Locker GY, Goranova T, Schatz P, Liu YZ, Hall MJ. Geographic and Ethnic Heterogeneity of Germline BRCA1 or BRCA2 Mutation Prevalence Among Patients With Metastatic Pancreatic Cancer Screened for Entry Into the POLO Trial. J Clin Oncol. 2020 May 1;38(13):1442-1454. doi: 10.1200/JCO.19.01890. Epub 2020 Feb 19. PubMed 32073954 ↗
  • Hammel P, Kindler HL, Reni M, Van Cutsem E, Macarulla T, Hall MJ, Park JO, Hochhauser D, Arnold D, Oh DY, Reinacher-Schick A, Tortora G, Algul H, O'Reilly EM, McGuinness D, Cui KY, Joo S, Yoo HK, Patel N, Golan T; POLO Investigators. Health-related quality of life in patients with a germline BRCA mutation and metastatic pancreatic cancer receiving maintenance olaparib. Ann Oncol. 2019 Dec 1;30(12):1959-1968. doi: 10.1093/annonc/mdz406. PubMed 31562758 ↗
  • Lowery MA, Kelsen DP, Capanu M, Smith SC, Lee JW, Stadler ZK, Moore MJ, Kindler HL, Golan T, Segal A, Maynard H, Hollywood E, Moynahan M, Salo-Mullen EE, Do RKG, Chen AP, Yu KH, Tang LH, O'Reilly EM. Phase II trial of veliparib in patients with previously treated BRCA-mutated pancreas ductal adenocarcinoma. Eur J Cancer. 2018 Jan;89:19-26. doi: 10.1016/j.ejca.2017.11.004. Epub 2017 Dec 8. PubMed 29223478 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal. All request will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Supporting information: Study protocol, Statistical analysis plan

Time frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Access criteria: When a request has been approved AstraZeneca will provide access to the de-identified individual patient-level data in an approved sponsored tool . Signed Data Sharing Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information. Additionally, all users will need to accept the terms and conditions of the SAS MSE to gain access. For additional details, please review the Disclosure Statements at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Data sharing details ↗ · astrazenecagroup-dt.pharmacm.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Dec 2014 to primary completion in Jan 2019, 48 months.

Results were first posted in Jan 2020, 1 year after primary completion.

Of 84 phase 3 interventional studies under Pancreatic Neoplasms, half reached primary completion within 58 months of starting (the median), counting those still running; a quarter within 36 and three quarters within 77. This study's 48 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 6, 2014
First posted
Jul 9, 2014
StartActual
Dec 16, 2014
Primary completionActual
Jan 15, 2019
CompletionActual
Jan 27, 2023
Results first posted
Jan 27, 2020
Last update
Sep 13, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 13, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02184195
Lead sponsor
AstraZeneca
Collaborators
Myriad Genetic Laboratories, Inc., Merck Sharp & Dohme LLC
Responsible party
Sponsor
First posted
Jul 9, 2014
Start date
Dec 16, 2014
Primary completion
Jan 15, 2019
Completion
Jan 27, 2023
Results posted
Jan 27, 2020
Last update
Sep 13, 2023

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Olaparib

Start the discussion